Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way

Andrea Mastrangelo; Angela Mammana; Piero Parchi

doi:10.1016/j.chembiol.2023.10.018

Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way

Cell Chem Biol. 2023 Nov 16;30(11):1340-1342. doi: 10.1016/j.chembiol.2023.10.018.

Authors

Andrea Mastrangelo¹, Angela Mammana², Piero Parchi³

Affiliations

¹ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
² IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
³ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy; IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy. Electronic address: [email protected].

PMID: 37977130
DOI: 10.1016/j.chembiol.2023.10.018

Abstract

Biofluid biomarkers to track neurodegenerative diseases in vitam are urgently needed. Recent studies show that large-scale proteomic analyses based on the proximity extension assay may reveal novel biomarkers reflecting disease pathophysiology. Such biomarkers will likely express their maximal clinical value when used in combination with pathology-specific biomarkers.

Publication types

Comment

MeSH terms

Biomarkers / analysis
Humans
Neurodegenerative Diseases*
Proteomics

Substances

Biomarkers